Company intelligence / Profile preview

XSXH Therapeutics

Calgary, Alberta, Canada

Ownership: Private
Development stage: Other

Overview

XORTX Therapeutics has multiple active clinical and preclinical programs. XRx-026 is at pre-NDA filing for gout, XRx-008 is in advanced clinical development for autosomal dominant polycystic kidney disease (ADPKD), XRx-101 is in clinical trials for acute kidney injury associated with COVID-19, and XRx-225 is at the preclinical stage for type 2 diabetic nephropathy. Their main mechanism is inhibition of xanthine oxidase and reduction of uric acid levels[1][2][3][6].

Therapeutic areas: NephrologyGastroenterologyRheumatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on XSXH Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XSXH Therapeutics.

Explore the full profile